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Abstract
CD248 (Endosialin) is a type 1 membrane protein involved in developmental and pathological angiogenesis through its
expression on pericytes and regulation of PDGFRb signalling. Here we explore the function of CD248 in skeletal muscle
angiogenesis. Two distinct forms of capillary growth (splitting and sprouting) can be induced separately by increasing
microcirculatory shear stress (chronic vasodilator treatment) or by inducing functional overload (extirpation of a synergistic
muscle). We show that CD248 is present on pericytes in muscle and that CD248-/- mice have a specific defect in capillary
sprouting. In contrast, splitting angiogenesis is independent of CD248 expression. Endothelial cells respond to pro-
sprouting angiogenic stimulus by up-regulating gene expression for HIF1a, angiopoietin 2 and its receptor TEK, PDGF-B and
its receptor PDGFRb; this response did not occur following a pro-splitting angiogenic stimulus. In wildtype mice, defective
sprouting angiogenesis could be mimicked by blocking PDGFRb signalling using the tyrosine kinase inhibitor Imatinib
mesylate. We conclude that CD248 is required for PDGFRb-dependant capillary sprouting but not splitting angiogenesis,
and identify a new role for CD248 expressed on pericytes in the early stages of physiological angiogenesis during muscle
remodelling.
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Introduction
Angiogenesis is the physiological process through which new
blood vessels are formed from cells of the existing vasculature. This
can be achieved by one of two processes, splitting or sprouting,
that require different levels of pericyte involvement (reviewed in
[1–2]). Splitting angiogenesis depends on the reorganisation of
existing cell populations, where opposing vascular endothelial cells
extend lamellipodia into the lumen until they contact with the
opposite side of the lumen, effectively splitting the vessel in two. In
contrast, sprouting angiogenesis is characterised by the migration
and proliferation of endothelial cells towards an angiogenic
stimulus in the tissue.
Pericytes play an essential role in stabilising the developing
vessel in sprouting angiogenesis [3]. Indeed, a loss or lack of
pericytes results in weaknesses in the capillaries, and has been
associated with micro-aneurysms and loss of sight [4–5]. Pericytes
are a heterogeneous population of perivascular cells located in
close proximity to endothelial cells beneath a common basement
membrane [2,6–7]. To date, no specific pan-pericyte marker has
been identified. Pericytes are defined as cells expressing either
platelet-derived growth factor receptor beta (PDGFRb), neuron
glial antigen 2 (NG2), alpha smooth muscle actin (aSMA) or
CD248 (endosialin) in close proximity to CD31 positive endothe-
lial cells (reviewed in [1,8]).
During physiological angiogenesis, platelet-derived growth
factor-B (PDGF-B) secreted by endothelial cells dimerises and
activates pericyte PDGFRb, which ultimately induces their
proliferation and migration towards the newly developing vessel
[5]. Importantly, lack of PDGFRb or PDGF-BB, and therefore
lack of pericyte function, results in the formation of disorganised
vessels leading to perinatally lethal haemorrhaging and oedema
[9–11].
CD248 (endosialin; tumour endothelial marker 1) is a C-type
lectin-like domain family member highly expressed during
embryogenesis [12], and upregulated on pericytes in vascularised
brain tumours and sarcomas [13–14]. Despite confusion in early
literature on the subject (eg. [15]), CD248 expression is not seen
on endothelial cells, but rather is a marker of neighbouring
pericytes and stromal cells where it has the potential to influence
the process of angiogenesis [16–17]. For example, tumour growth
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and large vessel formation in vivo are markedly reduced by genetic
deletion of CD248 [18] or removal of its cytoplasmic tail [19].
Similarly, antibody blockade of CD248 interfered with pericyte
migration and tube formation in vitro [12]. CD248 has also been
shown to regulate the kinetics of vessel pruning during develop-
mental vasculogenesis, ensuring only correctly organised and
viable vessels survive [20].
Recent evidence suggests that CD248 may exert its effects
through regulation of the PDGF pathway as PDGF-BB-induced
phosphorylation of extracellular signal-regulated kinase (ERK),
but not phosphorylation of PDGFRb itself, was markedly
diminished in CD248-deficient pericytes [21]. Thus, CD248
may function to enhance or modify PDGF-BB signalling acting
downstream of PDGFRb but upstream of ERK1/2 by an as yet
unknown mechanism.
CD248 is required for pathological angiogenesis and develop-
mental vasculogenesis [18–20]; however little is known about its
function in physiological angiogenesis and whether this differs
according to the form of capillary growth elicited (splitting vs.
sprouting). Here we have examined the role of CD248 within
skeletal muscle. Skeletal muscle displays a highly organised
microvascular network with a consistent relationship between
the number of capillaries and the number of muscle fibres; any
increase in the capillary to fibre ratio (C:F) strongly indicates an
angiogenic response [22–23]. We explored this relationship and
demonstrated that CD248-deficient mice display a specific defect
in sprouting, but not splitting, angiogenesis in skeletal muscle and
demonstrate for the first time that CD248-positive pericytes are
required during the early stages of physiological angiogenesis.
Methods
In vivo studies of angiogenesis
Male C57Bl/6 WT (Harlan, UK) and C57Bl/6 CD248-/- mice
(bred as described in Nanda et al. [18] donated by D.L. Huso,
Johns Hopkins Medical Institutions, Baltimore, MD, USA) were
studied between 8–12 weeks of age. All experiments were carried
out at the University of Birmingham, UK (project licence number
40/9475) following strict guidelines governed by the UK Animal
(Scientific Procedures) Act 1986 and approved by the local ethics
committee (BERSC: Birmingham Ethical Review Subcommittee).
Mice were housed in individually ventilated cages in groups of 3–6
individuals on a 12 hour light-dark cycle with ad libitum access to
standard laboratory mouse chow diet and water. 6 mice were used
for each experiment.
Extirpation of the tibialis anterior (TA) muscle was performed
under isoflurane general anaesthesia in aseptic conditions, to
produce overload of the synergist extensor digitorum longus
(EDL), as previously described [24]. Alternatively, prazosin
hydrochloride (50 mg/l; Tocris Bioscience, UK) supplemented
with 0.5 g/l granulated sucrose (Amresco, UK) was administrated
orally ad libitum in drinking water which was replaced every 3
days [25]. Imatinib mesylate (15 mg/ml in dH20; Santa Cruz
Biotechnology, USA) was administered daily by gavage, equivalent
to a therapeutic dose of 150 mg/kg/day [26].
Mice were carefully monitored throughout all treatment
programs by the Named Animal Care and Welfare Officer.
Opiate-based pain relief was administered for 24 hours following
surgical intervention. No weight loss or other adverse effects were
observed in response to any of the treatments given. All treatments
lasted for 7 days, after which time mice were sacrificed by cervical
dislocation. The EDL was dissected immediately and either snap
frozen in (i) liquid nitrogen-cooled isopentane for tissue sectioning
or (ii) liquid nitrogen for gene expression analysis. All samples were
stored at -80uC until use.
Immunofluorescence
Transverse 8 mm cryosections of the EDL muscle were cut at
220uC, air dried for 1 hr, fixed in acetone at 4uC for 20 minutes
and stored at 220uC until use. Sections were rehydrated and
blocked at room temperature for 30 minutes in phosphate buffered
saline (PBS) with 1% bovine serum albumin (PBSA; Sigma-
Aldrich, UK) for capillary: fibre ratio studies, or for 15–20 minutes
first in 0.05% Avidin, then 0.005% biotin and finally 10% horse
serum diluted in PBS (all from Sigma) for pericyte imaging.
Sections were incubated with the following primary antibodies for
1 hr at room temperature or overnight at 4uC: anti-CD31 (1:100:
AbD Serotec, BioRad, USA; clone 2H8); anti-CD248 (1:400;
clone p13, gift from Claire Isacke, The Institute of Cancer
Research, London, UK); anti-NG2 (1:75; Upstate, Merck
Millipore, USA; clone 132.38); anti-aSMA (1:100; Neomarkers,
ThermoScientific, USA; clone 1A4); anti-PDGFRb biotin (1:100;
eBioscience, USA; clone APB5), anti-collagen IV (1:200; Abcam,
Life Technologies, UK; polyclonal; ab19808), anti-phospho ERK
(1:100; Cell Signaling Technologies, UK; Phospho-p44/42
MAPK (Erk1/2) (Thr202/Tyr204) Antibody #9101). Subse-
quently, slides were incubated with secondary and then tertiary
antibodies and Hoechst 33342 (10 mg/ml; Invitrogen, UK) for 30–
60 min each before mounting with either Prolong Gold Antifade
(Molecular Probes, Life Technologies, UK) or Dabco (Sigma-
Aldrich, UK).
In some cases (Figure 1A, B and C), in order to visualise all
pericytes at once, tissues were incubated with a cocktail of primary
antibodies to PDGFRb, NG2 and aSMA which were detected
with specific secondary antibodies that all shared the same
fluorophore so that all pericytes, regardless of protein expression
phenotype, were visible at once. Alternatively, the pericyte
markers NG2, aSMA and CD248 were analysed on separate
tissue sections, each of which was counterstained with CD31 and
PDGFRb (Figure 1D).
Fluorescence microscopy and image analysis
For quantification of capillarity, images were acquired using a
Leica DM6000 fluorescence microscope controlled by Leica
Advanced Fluorescence software. A fibre was defined as an
isolated non-stained, convex area surrounded by collagen IV as
previously described [22]. A capillary was defined as a CD31-
positive structure that was ,8 mm in diameter that appears either
as a circle in cross section or elongated structures when sectioned
obliquely. Individual branches were counted as single capillaries.
Images were blinded prior to analysis. Figure S1 shows example
images from each genotype for control, prazosin and extirpated
mice. The differences in response to treatment become most
apparent following analysis of exact capillary and fibre number,
counted using Image J (NIH) and plotted as capillary to fibre ratio
(C:F) as previously described [22].
To determine pericyte phenotype, confocal images were
acquired for the entire muscle tissue section using a Zeiss LSM
510-UV confocal microscope, resolution (10246768 pixels per
image), magnification (x63) giving 120 mm by 120 mm for each co-
localisation image. The average number of capillaries counted per
field was 14 (range 3–28). Images were analysed using LSM Image
Browser (Zeiss). Capillaries were defined as above, and pericytes
defined as cells positive for $1 pericyte marker and located within
3 mm of a capillary. Pericyte coverage of capillaries was calculated
as the percentage of capillaries surrounded by cell bodies or cell
processes positive for $1 pericyte marker. For quantification of
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expression levels (phospho-ERK only) pixel counting was per-
formed using Zen pro 2012 imaging software (Carl Zeiss, UK). 2
images per section were taken from 3 separate mice. Results are the
sum of pixels with an expression intensity .10 normalised to
untreated control tissue.
Gene expression analysis by quantitative PCR
Messenger RNA (mRNA) was isolated from murine skeletal
muscle tissue using the RNeasy Fibrous Mini Kit (following
manufacturer’s instructions, Qiagen, UK) and stored at -80uC
until use. Isolated mRNA was converted to cDNA using High
Capacity cDNA conversion kit (as per manufacturer’s instructions;
Applied Biosystems, UK) in a Techne TC-Plus thermal cycler
(Techne, UK) and stored at220uC until use. Gene expression was
analysed by quantitative PCR (qPCR) on isolated cDNA with
TaqMan 2xPCR Master Mix (Applied Biosystems, Life Technol-
ogies, UK) and FAM-labelled primers (Assay on Demand kits from
Applied Biosystems, Life Technologies, UK). Samples were
amplified using the 7900HT Real-Time PCR machine and
analysed using SDS 2.2 (Applied Biosystems, Life Technologies,
UK). Data were expressed as relative expression units (22DCt)
relative to 18S.
Western blotting
Transverse frozen sections of EDL muscle (100620 mm
sections) were pooled for protein isolation in 50 ml RIPA buffer
(Sigma Aldrich, UK) containing a protease inhibitor cocktail
(Roche, UK: cOmplete, mini) phosphatase inhibitors (Roche, UK:
PhosSTOP phosphatase inhibitor tablets) as per manufacturer’s
instructions. Samples were incubated on ice for 30 minutes with
Figure 1. Phenotype of pericytes in wildtype and CD248 knockout skeletal muscle. Immunofluorescence and confocal microscopy of EDL
muscle sections from wildtype mice stained with antibodies to either (A) Collagen IV (green), CD31 (blue) and pericyte markers aSMA, NG2 and
PDGFRb (all red) or (B) CD248 (green), CD31 (blue), pericyte markers aSMA, NG2 and PDGFRb (all red) and nuclei (grey). CD248 was detected alone
(green – marked with arrow) or co-localised with the other pericyte markers (yellow – marked with star). Enlarged region (dashed box) shows a
pericyte (red) surrounded by the collagen IV basement membrane. (C) Pericyte coverage expressed as a percentage of CD31 positive vessels positive
for $1 pericyte marker. (D) Expression of individual pericyte markers, expressed as percentage of CD31 positive vessels positive for either PDGFRb,
NG2 or aSMA. Empty bars are WT, filled bars are CD248-/-. Data are mean6 SEM from 3 independent animals. N.E = not expressed. ns = no significant
difference assessed by (C) t-test or (D) ANOVA with Bonferroni post-test. Scale bars are 50 microns.
doi:10.1371/journal.pone.0107146.g001
CD248 Is Required for Sprouting Angiogenesis
PLOS ONE | www.plosone.org 3 September 2014 | Volume 9 | Issue 9 | e107146
periodic vortexing. Insoluble debris was removed using QiASh-
redder columns (Qiagen, UK) and samples were boiled in SDS
page buffer for 5 minutes. Criterion TGX precast gels (Bio-Rad,
UK) were used for electrophoresis and protein was transferred
using the trans-blot turbo transfer system (Bio-Rad, UK).
Membranes were blocked in 5% non-fat milk in TBS containing
0.1% Tween-20. Primary antibodies were incubated at a 1:1000
dilution performed overnight at 4uC in block. Primary antibodies
were as follows: Total ERK (Cell Signaling Technologies, UK,
p44/42 MAPK (Erk1/2) clone #9102), phospho-ERK (Cell
Signaling Technologies, UK, Phospho-p44/42 MAPK (Erk1/2)
(Thr202/Tyr204) clone #9101). Anti-rabbit HRP-linked second-
ary antibody (Cell Signaling Technologies, UK, #7074) was used
at 1:1000 for 1 hour at room temperature. ECL Western blotting
substrate (Pierce, UK) reagent was used to visualise the resulting
bands.
Statistical analysis
Data are presented as mean 6 SEM of n experiments.
Variation between multiple treatments was evaluated using
analysis of variance (ANOVA) followed by Bonferroni post-hoc
test. Where appropriate, differences between individual treatments
were evaluated by unpaired t-test unless stated otherwise in the
figure legend. P values,0.05 were considered statistically signif-
icant.
Results
CD248 is expressed in skeletal muscle by a subset of
pericytes
We initially characterised the phenotype of pericytes in resting
skeletal muscle from wildtype (WT) and CD248-/- animals.
Pericytes were identified histologically with a panel of antibodies
against PDGFRb, NG2 and aSMA and clearly visible under the
collagen IV basement membrane in close association with CD31-
positive capillaries (Figure 1A). In both WT and CD248-/- tissue
almost all CD31 positive vessels within the skeletal muscle (.90%)
were associated with pericyte cell bodies or processes (Figure 1C)
expressing a heterogeneous mix of PDGFRb, NG2 and aSMA
(Figure 1D), thus confirming previous studies demonstrating that
pericyte processes cover 99% of capillary length in normal skeletal
muscle [6]. CD248 was visible on some of these pericytes
(Figure 1B, examples marked with a star) and also occasionally
on cells where none of the three other pericyte markers used were
detectable (Figure 1B, example marked with an arrow). There
were no significant differences in pericyte coverage (Figure 1C), or
expression of the different pericyte markers in tissue from
CD248-/- compared to WT mice (Figure 1D). The majority of
pericytes were positive for PDGFRb, with 60-80% expressing
NG2 and/or CD248, and ,40% positive for aSMA (Figure 1D).
Approximately 45% of CD248 positive pericytes also expressed
PDGFRb (data not shown). As expected, CD248 expression on
pericytes was not expressed (NE) in CD248-/- muscle tissue
(Figure 1D) but this did not affect the relative expression of other
markers. Following extirpation of WT mice we also found no
statistically significant differences in the expression of any of the
four pericyte markers (Figure S2).
WT and CD248-/- muscle display the same characteristics
before treatment
As pericytes are critical for the stabilisation of the capillary
network, we sought to examine whether genetic deletion of CD248
could affect the normal architecture of the capillary network in
skeletal muscle. We observed no difference in the capillary density
(CD) or the capillary to fibre ratio (C:F) in WT and CD248-/-
animals at baseline (Figure 2A and B respectively). Similarly, both
WT and CD248-/- showed the same inverse, non-linear relation-
ship between CD and fibre size as previously described [23], with
CD progressively declining as the area of the fibre increased
(Figure 2C). No overt phenotypic differences in the organisation of
the capillary network were observed between WT and CD248-/-
by confocal microscopy (Figure 2D).
Both WT and CD248-/- mice mount a splitting angiogenic
response induced by prazosin treatment
We used prazosin to increase blood flow within skeletal muscle,
thereby increasing shear stress and inducing a splitting angiogenic
response [25]. As expected, we observed a significant increase in
C:F ratio following treatment in WT animals and a similar
increase was seen in the CD248-/- muscle (Figure 3A), thus
suggesting CD248 is not required for splitting angiogenesis.
CD248-/- mice are unable to mount a sprouting
angiogenic response to muscle overload
Sprouting angiogenesis requires extensive pericyte involvement
to co-ordinate endothelial cell migration [2,27–28]. We examined
the potential importance of CD248 in this process in vivo by using
surgical extirpation of the tibialis anterior muscle. This procedure,
causing overload in the EDL muscle, triggers a compensatory
angiogenic response based only on sprouting that can be observed
in the operated limb in rats [3,24] and in mice [29–30]. Induction
of sprouting angiogenesis in WT animals was demonstrated by a
significant increase in C:F when compared to untreated, control
mice (Figure 3B), as previously described [24]. In contrast, this
response was completely ablated in CD248-/- animals (Figure 3B),
indicating that CD248 is required for sprouting angiogenesis in
this model of muscle remodelling. Of note, we observed no
gender-specific differences in these responses for either genotype
(data not shown).
Recent evidence suggests that CD248 may function to enhance
or modify PDGF-BB signalling by acting upstream of ERK1/2
phosphorylation in pericytes [21]. In skeletal muscle, we observed
an up-regulation of ERK phosphorylation following extirpation in
the WT but not in the CD248-/- muscle by Western blot
(Figure 3E) and immunofluorescence (Figure 3F). Interestingly,
extirpation-induced ERK phosphorylation was ablated with
Imatinib treatment (Figure 3E–F). Collectively these data support
the concept that CD248 modulation of PDGF-BB signalling
occurs upstream of ERK phosphorylation.
We next aimed to evaluate the response of genes known to
regulate the angiogenic response by using quantitative RT PCR
(Figure 4). In both WT and CD248-/- mice, extirpation signifi-
cantly increased the levels of PDGF-B and its receptor PDGF
receptor b, angiopoietin 2 and HIF1a mRNA (Figure 4). A
moderate but insignificant increase was also observed for the
angiopoietin receptor homologue of Tie2, TEK (Figure 4B).
Prazosin treatment did not induce the expression of these genes
in either WT or CD248-/- animals. Tissue-wide expression of
VEGF-A mRNA expression was not altered following either
extirpation or prazosin treatment regardless of CD248 genotype
(Figure 4E). The effects of these treatments on HIF1a, VEGF-A
and Ang2 expression are broadly in agreement with previous
findings [29]. To our knowledge the effect of extirpation or
prazosin treatment on the expression of the other genes shown
here has not been previously reported in the literature.
CD248 Is Required for Sprouting Angiogenesis
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Wildtype mice treated with Imatinib mesylate mirror the
defect in sprouting angiogenesis observed in CD248-/-
mice
CD248 is known to be required for effective PDGF signalling in
pericytes [21] therefore we tested whether selective inhibition of
PDGF signalling could replicate the CD248-/- phenotype that we
observed in the sprouting angiogenic response to muscle overload.
Imatinib mesylate is a tyrosine kinase inhibitor of Bcr Abl chimeric
protein, c Kit and a competitive inhibitor of PDGF signalling,
known to effectively block phosphorylation of the PDGF Receptor
b thereby preventing downstream signalling [26]. Imatinib
treatment alone had no effect on C:F ratio in untreated WT or
CD248-/- mice when compared to genotype-matched controls.
Similarly, Imatinib treatment had no effect on the prazosin-
induced increase in C:F in either WT or CD248-/- mice
(Figure 3C), implying that PDGF signalling is not required for
splitting angiogenesis. In contrast, Imatinib completely abolished
extirpation-induced angiogenesis in WT mice (Figure 3D), mir-
roring the effect of CD248 knockout (Figure 3B).
Interestingly, Imatinib prevented the up-regulation of PDGF-B,
PDGFRb, angiopoietin 2, TEK and HIF1a mRNA in both WT
and CD248-/- muscle (Figure 5), suggesting the dependency of all
Figure 2. Effects of CD248-/- on the architecture of skeletal muscle in control animals. (A) Average capillary density (capillary/mm2) and (B)
capillary to fibre ratio were determined from tissue sections of untreated EDL muscle by immunofluorescence. In (A) and (B) each point represents
the mean value obtained for 3–5 sections per animal. The mean for all animals is represented by the wide line and the error bars show the 95%
confidence interval. (C) In both genotypes a non-linear relationship is seen between muscle fibre size and capillary density. Empty circles are WT,
filled circles are CD248-/-. Each circle represents the mean value for one animal, subjected to control, extirpation or prazosin treatment. (D)
Immunofluorescence and confocal microscopy of EDL tissue sections from untreated 8-12 week old wildtype (top) or CD248-/- (bottom) mice.
Sections were stained with antibodies to Collagen IV (blue) to mark the basement membrane and CD31 (red/magenta) to mark the blood vessels.
Scale bars are 50 microns. ns = no significant difference by t-test.
doi:10.1371/journal.pone.0107146.g002
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these genes on the PDGF signalling pathway. Again, no change
was seen in VEGF-A mRNA expression following Imatinib
treatment, regardless of genotype (Figure 5E).
Discussion
Appropriate regulation of angiogenesis is crucial in allowing
tissues to respond to changing physiological requirements and
pericytes are known to play a crucial role in the control of these
processes. In this manuscript we have shown that CD248 is
expressed on some, but not all, pericytes surrounding the
capillaries within resting muscle tissue and we have demonstrated
a role for CD248 in sprouting angiogenesis. PDGFRb and NG2
are widely used as pericyte markers, but are neither specific for
pericytes nor expressed on all pericytes at all times [28]. While
CD248 sometimes co-localised with PDGFRb and NG2, CD31
positive capillaries were also seen closely surrounded by CD248
single-positive perivascular cells, in a location expected to be
occupied by pericytes i.e. within the collagen IV basement
membrane. This suggests that CD248 can be useful in identifying
a pericyte subset that would otherwise be missed if only the
traditional pericyte markers are used.
Angiogenesis can occur via a process of vessel splitting, where
one vessel is reorganised longitudinally to become two, or by
sprouting where an entirely new vessel is formed [1]. Prazosin
causes an increase in microvascular flow through an a-adrenore-
ceptor antagonised arteriolar relaxation [31], elevating shear stress
on the luminal capillary walls and triggering angiogenesis by
longitudinal splitting. This is a mostly pericyte-independent
process occurring through reorganisation of the endothelium with
little requirement for basement membrane remodelling or an
increase in pericyte number [3]. Our results demonstrate that
muscle is able to effectively mount a microvascular response to
increased shear stress in CD248-/- mice.
CD248-/- mice were unable to mount a sprouting angiogenic
response to extirpation-induced overload of the EDL muscle.
Extirpation causes increased stretch on myocytes, seen as an
increase in sarcomere length that leads to hypertrophy and
hyperplasia, releasing growth factors into the local environment,
and increasing stretch on the abluminal surface of adjacent
capillaries [31]. This physical stretch is the trigger for abluminal
sprouting as the sole mechanism of capillary growth, a mechan-
otransduction process which requires pericyte migration and
activation. The observation that CD248-/- mice are unable to
respond to these stimuli strongly suggests that CD248 expression
on pericytes is required in the cascade of events leading to capillary
sprout formation. Additionally, we observed that members of the
PDGF, angiopoietin and HIF1a signalling pathways were
upregulated only by extirpation and not by prazosin treatment.
This extends the differential gene expression profile previously
described between splitting and sprouting angiogenesis [29]. By
Western blotting and immunofluorescence analysis we were able
to show that phosphorylation of ERK occurs following extirpation
in the WT but not the CD248-/- muscle and that this
phosphorylation can be blocked with Imatinib treatment, further
implicating CD248 and the PDGF signalling cascade in this
process.
Combining evidence in the literature and this most recent study,
we propose the following model (Figure 6): when endothelial cells
are subjected to mechanical stretch, such as that seen following
extirpation, the transcription factor HIF-1a is up-regulated [32]
and can bind to the angiopoietin 2 HIF-binding site resulting in
up-regulation of angiopoietin mRNA [33]. Ang2 is known to be
strongly upregulated at sites of active vessel remodelling [34]
where it binds the receptor TEK on endothelial cells, inducing its
phosphorylation [35]. This results in the up-regulation of PDGF-B
protein which dimerises and binds to its receptor PDGFRb on
pericytes. In the presence of CD248, PDGFRb signalling occurs
which stimulates the migration of pericytes towards the endothe-
lium and subsequently stabilises the capillary. Successful sprouting
angiogenesis reduces the stretch experienced in the capillary bed,
restoring HIF1a and angiopoietin gene expression to baseline
levels. In the CD248-/- mouse sprouting cannot occur due to
defective PDGF signalling resulting in persistently high levels of
stretch and expression of its inducible genes, HIF1a, Ang2, TEK,
PDGF-B and PDGFRb.
We have to assume that PDGF signalling can occur normally in
the absence of CD248 in most situations, and in cells where
CD248 is not expressed (such as endothelial cells [36]). This is
evidenced by the fact that the CD248-/- mouse does not
phenocopy the PDGF-B or PDGFRb knockout mice, both of
which are embryonically lethal due to widespread microvascular
bleeding caused by a severe shortage of vascular smooth muscle
cells and pericytes [9–11]. In contrast, the CD248-/- has no overt
phenotype and no increased mortality (unpublished observations).
Imatinib blocks PDGF signalling in all cell types and by measuring
its effects on mRNA expression within whole muscle we were
unable to distinguish CD248-mediated PDGF signalling from
non-CD248-mediated. Interestingly, Imatinib blocked up-regula-
tion of HIF1a, TEK2, Ang2, PDGF-B and PDGFRb mRNA
whilst their expression was not prevented in the CD248-/- mouse.
This can be explained by the non-specific nature of the inhibitor
used. Recently, Chislock et al. [37] reported that Abelson (Abl)
kinases (a target for Imatinib in addition to PDGFRb) positively
regulated TEK expression, explaining the reduction in the mRNA
levels of this receptor following Imatinib treatment. In addition,
Imatinib has been reported to reduce HIF1a protein expression in
a model of prostate cancer by a hypoxia-independent process [38].
Given these findings, it is clear that Imatinib treatment can result
in the blockade of many aspects of the HIF1a/angiopoietin/
PDGF signalling process making it difficult to draw firm
conclusions as to the exact role of CD248 within the cascade.
Unfortunately, no specific PDGF-pathway inhibitors are available
Figure 3. Effect of Prazosin and Extirpation treatment on muscle angiogenesis. Effects of (A) prazosin treatment (Pra) and (B) extirpation
(Ext) on the capillary to fibre ratio (C:F) in wildtype and CD248-/-mice. The capillary to fibre ratio (C:F) was calculated for each group. Alternatively mice
underwent (C) prazosin treatment or (D) extirpation surgery either alone or in the presence (+) or absence (-) of the PDGF inhibitor Imatinib (150 mg/
kg/day). In each case, control animals received no treatment. Empty bars are WT, filled bars are CD248-/-. (E) Western blot of EDL muscle from WT and
CD248-/- mice undergoing extirpation (Ext) surgery either alone or in the presence (+) or absence (-) of the PDGF inhibitor Imatinib (Imat) at 150 mg/
kg/day. Upper blot shows levels of phospho-ERK expression whilst the lower blot is a loading control showing levels of total ERK. (F) Top:
Representative images of phospho-ERK expression by confocal microscopy from control, extirpated (Ext) and extirpated plus Imatinib (Imat).
Phospho-ERK (green) nuclei (grey). Scale bar is 50 microns. Below: Pixel counts (expressed as fold change from genotype-matched control) from
confocal immunofluorescence images of phosphorylated ERK from muscle sections with (+) and without (-) extirpation (Ext) and/or Imatinib (Imat)
treatment. Data are mean 6 SEM from 6 animals (A-D) and 3 animals (E–F). (A–D) ANOVA with Bonferroni post-test shows a significant effect of
treatment and genotype on the response to stimulus. (F) Students t-test was used to identify significance * = P,0.05, ** = P,0.01, *** = P,0.001,
ns = non-significant.
doi:10.1371/journal.pone.0107146.g003
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to allow us to further dissect the role of PDGF signalling in this
model of sprouting angiogenesis.
Whilst the nature of the interaction of Imatinib with the PDGF
pathway is understood, its influence of CD248 on this pathway
remains unclear. Tomkowicz et al. [21] reported that CD248
interacts downstream of the PDGF receptor and upstream of ERK
by an unknown mechanism and with unknown intermediaries.
Our results show that the induction of PDGF-B by endothelial
cells and PDGFRb by pericytes at the gene level does not require
CD248. However, downstream effects of CD248-mediated PDGF
signalling that result in sprouting angiogenesis in this context seem
to be dependent on CD248 expression. The intricacies of PDGF
signalling have been exposed by the creation of an allelic series of
PDGFRb mice in which specific tyrosine residues were replaced
with phenylalanine (reviewed in detail in [39–40]). All mouse
strains generated were viable and fertile even when all 7 of the
tyrosines that are known to be involved in PDGFRb signalling
were removed. This, compared to the PDGFRb knockout, which
Figure 4. Effect of CD248 genotype on transcriptional response to Prazosin and Extirpation treatment. mRNA analysis of EDL muscle
tissue by RT-PCR from WT and CD248-/- mice following either no treatment control (-), extirpation (ext) or prazosin (pra) treatment. Gene transcription
data were acquired for angiopoietin2 (Ang2: A), endothelial tyrosine kinase (TEK: B), platelet-derived growth factor B (PDGF-B: C), platelet-derived
growth factor receptor b (PDGFRb: D), vascular endothelial growth factor A (VEGF-A: E) and hypoxia-inducible factor 1a (HIF1a: F). Data are shown as
relative expression units (22DCt) relative to 18S. Data are mean6 SEM from 6 animals. ANOVA with Bonferroni post-test shows a significant effect of
treatment and genotype on the response to stimulus * = P,0.05; ** = P,0.01, *** = P,0.001, ns = non-significant.
doi:10.1371/journal.pone.0107146.g004
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is lethal at E18.5 [40] suggests that PDGFRb has signalling
capacity in the cytoplasmic tail beyond that of tyrosine phosphor-
ylation. How CD248 interacts with the PDGF pathway has yet to
be identified and is crucial in order to extend our understanding of
this vital signalling pathway.
Figure 5. Effect of PDGF signalling inhibition by Imatinib on gene expression following Prazosin and Extirpation treatment. mRNA
analysis of EDL muscle tissue by RT-PCR from WT and CD248-/- mice plus no treatment control (-), extirpation (ext) or prazosin (pra) treatment. In
addition, all mice were treated with Imatinib throughout the experiment. Gene transcription data were acquired for angiopoietin2 (Ang2: A),
endothelial tyrosine kinase (TEK: B), platelet-derived growth factor B (PDGF-B: C), platelet-derived growth factor receptor b (PDGFRb: D), vascular
endothelial growth factor A (VEGF-A: E) and hypoxia-inducible factor 1a (HIF1a: F). Data are shown as relative expression units (22DCt) relative to
18S. Data are mean 6 SEM from 6 animals. ANOVA with Bonferroni post-test was performed and no significant differences were observed between
any treatments or genotypes.
doi:10.1371/journal.pone.0107146.g005
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Supporting Information
Figure S1 Confocal images used for capillary:fibre ratio
analysis. Frozen sections from WT or CD248-/- mice either
untreated, extirpated or prazosin treated. Sections were stained
with antibodies to collagen IV (blue) to stain basement membrane
and demarcate the fibre boundaries or CD31 (red/magenta) to
mark capillaries. Images are representative of 3-6 animals per
group. Scale bars are 50 microns.
(TIFF)
Figure S2 Expression of individual pericyte markers
following either sham operation or extirpation, ex-
pressed as percentage of CD31 positive vessels positive
for either PDGFRb, NG2 or aSMA. Data are mean +2 SEM
from 3 independent WT animals. ns = no significant difference by
ANOVA with Bonferroni post-test.
(TIFF)
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